Publications by authors named "N Simioni"
Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.
Nutr Metab Cardiovasc Dis
November 2021
Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is common in people with type 2 diabetes (T2D) and can progress to advanced fibrosis and cirrhosis. In this retrospective study, we explored the longitudinal changes in markers of hepatic steatosis and fibrosis during T2D treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Methods: We analysed observational data from six diabetes outpatient clinics.
Article Synopsis
- A study was conducted in North-East Italy to evaluate how patients with Type 2 Diabetes (T2D) could reduce their basal-bolus insulin (BBI) after starting a GLP-1 receptor agonist (GLP-1RA) treatment.
- Out of 425 patients analyzed, about 58.6% were able to de-intensify their insulin therapy, particularly those who were younger, had less severe diabetes, and had better initial blood sugar levels.
- The findings suggest that starting GLP-1RA can lead to a significant reduction in insulin use, with improved HbA1c levels in patients who successfully de-intensified their BBI.
Introduction: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA liraglutide (IDegLira) represents an improvement to this therapy. We have conducted a real-world evidence study in Italian patients with T2DM to evaluate whether the encouraging clinical trial results obtained with IDegLira, which became available in Italy in January 2018, can be confirmed in Italian clinical practice.
View Article and Find Full Text PDFContext: In randomized controlled trials (RCTs) on type 2 diabetes (T2D) patients, the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-RA) dulaglutide reduced HbA1c and body weight, but generalizability of such findings to real-world T2D patients is challenging.
Objective: We evaluated effectiveness of dulaglutide in routine clinical practice, especially in subgroups of patient that are underrepresented in RCTs.
Design: Retrospective multicenter study.
Introduction And Aim: Real-word data on the head-to-head comparisons among glucagon-like peptide-1 receptor agonists (GLP-1RA) are scant. Therefore, we aimed to compare the effectiveness of dulaglutide versus liraglutide and exenatide once weekly (exeOW) in type 2 diabetic (T2D) patients under routine care.
Methods: This was a retrospective, multicenter, real-world study on patients with T2D (aged 18-80) initiating a GLP-1RA between 2010 and 2018 at specialist outpatient clinics.